Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCMDVR)

Drug Name

Triptolide Drug Info

Synonyms

triptolide; 38748-32-2; Triptolid; PG490; UNII-19ALD1S53J; NSC 163062; CHEMBL463763; CHEBI:9747; 19ALD1S53J; C20H24O6; PG-490; CPD000466307; Triptolide, Tripterygium wilfordii; (-)-Triptolide; PG 490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; SMR000466307; NSC163062; Triptolide, 1; Triptolide(PG490)/; AC1Q6AXN; BSPBio_001595; KBioGR_000315; KBioSS_000315

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Phase 3	[1]

Cross-matching ID

PubChem CID: 107985
ChEBI ID: CHEBI:9747
CAS Number: CAS 38748-32-2
TTD Drug ID: DMCMDVR
INTEDE Drug ID: DR1904

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nuclear factor NF-kappa-B (NFKB)	TTSXVID	NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	Highest Status	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Phase 3	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Nuclear factor NF-kappa-B (NFKB)	DTT	NFKB1	5.38	4.436	4.89	5.698
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	11.692	6.58	4.984	9.089

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Autoimmune diabetes

ICD Disease Classification

5A10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.85E-01	2.24E-02	7.33E-02

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT02115659) Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). U.S. National Institutes of Health.
2	Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
3	Preclinical pharmacokinetics of triptolide: a potential antitumor drug. Curr Drug Metab. 2019;20(2):147-154.